Highlights

array(40) {
  [0]=>
  string(4) "9263"
  ["article_id"]=>
  string(4) "9263"
  [1]=>
  string(26) "PharmaMarketing USA Summit"
  ["article_title"]=>
  string(26) "PharmaMarketing USA Summit"
  [2]=>
  string(150) "We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the exquisite Four Seasons Westlake"
  ["short_description"]=>
  string(150) "We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the exquisite Four Seasons Westlake"
  [3]=>
  string(507) "We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the exquisite Four Seasons Westlake Village in California. This summit will unite leading pharmaceutical marketing executives and innovative sponsors in an exclusive networking environment.&#nlThe event's content has been meticulously curated to tackle key challenges and interests in pharma marketing, highlighting relevant market developments and presenting practical, progressive id..."
  ["description"]=>
  string(507) "We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the exquisite Four Seasons Westlake Village in California. This summit will unite leading pharmaceutical marketing executives and innovative sponsors in an exclusive networking environment.&#nlThe event's content has been meticulously curated to tackle key challenges and interests in pharma marketing, highlighting relevant market developments and presenting practical, progressive id..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(58) "https://www.pharmiweb.com/event/pharmamarketing-usa-summit"
  ["blog_url"]=>
  string(58) "https://www.pharmiweb.com/event/pharmamarketing-usa-summit"
  [15]=>
  string(19) "2023-12-22 10:34:11"
  ["add_date"]=>
  string(19) "2023-12-22 10:34:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:55"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

PharmaMarketing USA Summit

We are thrilled to announce the upcoming PharmaMarketing Summit, scheduled to take place on February 8-9, 2023, at the e

array(40) {
  [0]=>
  string(4) "9073"
  ["article_id"]=>
  string(4) "9073"
  [1]=>
  string(98) "Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel Syndrome"
  ["article_title"]=>
  string(98) "Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel Syndrome"
  [2]=>
  string(150) "Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company f"
  ["short_description"]=>
  string(150) "Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company f"
  [3]=>
  string(251) "Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the..."
  ["description"]=>
  string(251) "Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(50) "https://www.drugs.com/nda/glepaglutide_231222.html"
  ["blog_url"]=>
  string(50) "https://www.drugs.com/nda/glepaglutide_231222.html"
  [15]=>
  string(19) "2023-12-22 08:12:10"
  ["add_date"]=>
  string(19) "2023-12-22 08:12:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel

Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 200450

array(40) {
  [0]=>
  string(4) "9047"
  ["article_id"]=>
  string(4) "9047"
  [1]=>
  string(213) "Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, 8.4% Sodium Bicarbonate Injection, and Atropine Sulfate Injection Due to the Potential Presence of Glass Particulate Matter"
  ["article_title"]=>
  string(213) "Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, 8.4% Sodium Bicarbonate Injection, and Atropine Sulfate Injection Due to the Potential Presence of Glass Particulate Matter"
  [2]=>
  string(150) "Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed i"
  ["short_description"]=>
  string(150) "Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed i"
  [3]=>
  string(250) "Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Glass Syringe, 5 mEq/10..."
  ["description"]=>
  string(250) "Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Glass Syringe, 5 mEq/10..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(129) "https://www.drugs.com/fda/hospira-inc-issues-voluntary-nationwide-recall-4-2-sodium-bicarbonate-8-4-sodium-bicarbonate-14646.html"
  ["blog_url"]=>
  string(129) "https://www.drugs.com/fda/hospira-inc-issues-voluntary-nationwide-recall-4-2-sodium-bicarbonate-8-4-sodium-bicarbonate-14646.html"
  [15]=>
  string(19) "2023-12-21 20:49:00"
  ["add_date"]=>
  string(19) "2023-12-21 20:49:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection,

Audience: Health Professional, Pharmacy December 21, 2023 - NEW YORK, NY., Hospira, Inc., a Pfizer company, is voluntari

array(40) {
  [0]=>
  string(4) "9048"
  ["article_id"]=>
  string(4) "9048"
  [1]=>
  string(213) "Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAINâ„¢ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter"
  ["article_title"]=>
  string(213) "Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAINâ„¢ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter"
  [2]=>
  string(165) "Audience: Health Professional, Pharmacy &#nl&#nl&#nl&#nl&#nlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bl"
  ["short_description"]=>
  string(165) "Audience: Health Professional, Pharmacy &#nl&#nl&#nl&#nl&#nlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bl"
  [3]=>
  string(256) "Audience: Health Professional, Pharmacy &#nl&#nl&#nl&#nl&#nlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot..."
  ["description"]=>
  string(256) "Audience: Health Professional, Pharmacy &#nl&#nl&#nl&#nl&#nlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(131) "https://www.drugs.com/fda/hospira-inc-issues-voluntary-nationwide-recall-one-lot-bleomycin-usp-15-units-single-onco-tain-14644.html"
  ["blog_url"]=>
  string(131) "https://www.drugs.com/fda/hospira-inc-issues-voluntary-nationwide-recall-one-lot-bleomycin-usp-15-units-single-onco-tain-14644.html"
  [15]=>
  string(19) "2023-12-21 20:28:00"
  ["add_date"]=>
  string(19) "2023-12-21 20:28:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection,

Audience: Health Professional, Pharmacy &#nl&#nl&#nl&#nl&#nlDecember 21, 2023 - NEW YORK, NY. Hospira, Inc., a Pfizer co

array(40) {
  [0]=>
  string(4) "9112"
  ["article_id"]=>
  string(4) "9112"
  [1]=>
  string(84) "First Rheumatoid Arthritis Patient Dosed in Phase â…¢ Clinical Study of LNK01001"
  ["article_title"]=>
  string(84) "First Rheumatoid Arthritis Patient Dosed in Phase â…¢ Clinical Study of LNK01001"
  [2]=>
  string(158) "BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovat"
  ["short_description"]=>
  string(158) "BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovat"
  [3]=>
  string(260) "BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis..."
  ["description"]=>
  string(260) "BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(119) "https://www.drugs.com/clinical_trials/first-rheumatoid-arthritis-patient-dosed-phase-clinical-study-lnk01001-21240.html"
  ["blog_url"]=>
  string(119) "https://www.drugs.com/clinical_trials/first-rheumatoid-arthritis-patient-dosed-phase-clinical-study-lnk01001-21240.html"
  [15]=>
  string(19) "2023-12-21 12:12:39"
  ["add_date"]=>
  string(19) "2023-12-21 12:12:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

First Rheumatoid Arthritis Patient Dosed in Phase â…¢ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as '

array(40) {
  [0]=>
  string(4) "9074"
  ["article_id"]=>
  string(4) "9074"
  [1]=>
  string(51) "Merck Provides U.S. Regulatory Update on Gefapixant"
  ["article_title"]=>
  string(51) "Merck Provides U.S. Regulatory Update on Gefapixant"
  [2]=>
  string(150) "RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the "
  ["short_description"]=>
  string(150) "RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the "
  [3]=>
  string(246) "RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding..."
  ["description"]=>
  string(246) "RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(48) "https://www.drugs.com/nda/gefapixant_231220.html"
  ["blog_url"]=>
  string(48) "https://www.drugs.com/nda/gefapixant_231220.html"
  [15]=>
  string(19) "2023-12-20 10:12:45"
  ["add_date"]=>
  string(19) "2023-12-20 10:12:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Merck Provides U.S. Regulatory Update on Gefapixant

RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Can

array(40) {
  [0]=>
  string(4) "9113"
  ["article_id"]=>
  string(4) "9113"
  [1]=>
  string(197) "Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia"
  ["article_title"]=>
  string(197) "Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia"
  [2]=>
  string(156) "&#nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005)&#nlAll six key seconda"
  ["short_description"]=>
  string(156) "&#nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005)&#nlAll six key seconda"
  [3]=>
  string(244) "&#nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005)&#nlAll six key secondary endpoints, including patient global impression, fibromyalgia-specific symptoms and..."
  ["description"]=>
  string(244) "&#nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005)&#nlAll six key secondary endpoints, including patient global impression, fibromyalgia-specific symptoms and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(143) "https://www.drugs.com/clinical_trials/tonix-pharmaceuticals-announces-highly-statistically-significant-clinically-meaningful-topline-21250.html"
  ["blog_url"]=>
  string(143) "https://www.drugs.com/clinical_trials/tonix-pharmaceuticals-announces-highly-statistically-significant-clinically-meaningful-topline-21250.html"
  [15]=>
  string(19) "2023-12-20 10:12:14"
  ["add_date"]=>
  string(19) "2023-12-20 10:12:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful

&#nlPhase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint,

array(40) {
  [0]=>
  string(4) "9114"
  ["article_id"]=>
  string(4) "9114"
  [1]=>
  string(71) "Marburg vaccine tested at Texas Biomed moves to Phase 2 clinical trials"
  ["article_title"]=>
  string(71) "Marburg vaccine tested at Texas Biomed moves to Phase 2 clinical trials"
  [2]=>
  string(150) "SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is progressing in clinical trials, mo"
  ["short_description"]=>
  string(150) "SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is progressing in clinical trials, mo"
  [3]=>
  string(257) "SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is progressing in clinical trials, moving a step closer towards becoming the world's first vaccine against the deadly virus.&#nlThe Sabin..."
  ["description"]=>
  string(257) "SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is progressing in clinical trials, moving a step closer towards becoming the world's first vaccine against the deadly virus.&#nlThe Sabin..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(114) "https://www.drugs.com/clinical_trials/marburg-vaccine-tested-texas-biomed-moves-phase-2-clinical-trials-21222.html"
  ["blog_url"]=>
  string(114) "https://www.drugs.com/clinical_trials/marburg-vaccine-tested-texas-biomed-moves-phase-2-clinical-trials-21222.html"
  [15]=>
  string(19) "2023-12-20 09:12:42"
  ["add_date"]=>
  string(19) "2023-12-20 09:12:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Marburg vaccine tested at Texas Biomed moves to Phase 2 clinical trials

SAN ANTONIO, Dec. 19, 2023. A Marburg virus vaccine tested at Texas Biomedical Research Institute (Texas Biomed) is prog

array(40) {
  [0]=>
  string(4) "9115"
  ["article_id"]=>
  string(4) "9115"
  [1]=>
  string(103) "ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion"
  ["article_title"]=>
  string(103) "ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion"
  [2]=>
  string(150) "SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio pl"
  ["short_description"]=>
  string(150) "SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio pl"
  [3]=>
  string(246) "SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative..."
  ["description"]=>
  string(246) "SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(133) "https://www.drugs.com/clinical_trials/chemdiv-helps-advance-viriom-s-influenza-successful-phase-clinical-trials-completion-21223.html"
  ["blog_url"]=>
  string(133) "https://www.drugs.com/clinical_trials/chemdiv-helps-advance-viriom-s-influenza-successful-phase-clinical-trials-completion-21223.html"
  [15]=>
  string(19) "2023-12-20 09:12:02"
  ["add_date"]=>
  string(19) "2023-12-20 09:12:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Tria

SAN DIEGO, Dec. 19, 2023. ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies b

array(40) {
  [0]=>
  string(4) "9063"
  ["article_id"]=>
  string(4) "9063"
  [1]=>
  string(96) "FDA Approves Filsuvez (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa"
  ["article_title"]=>
  string(96) "FDA Approves Filsuvez (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa"
  [2]=>
  string(150) "BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies"
  ["short_description"]=>
  string(150) "BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies"
  [3]=>
  string(249) "BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug..."
  ["description"]=>
  string(249) "BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(114) "https://www.drugs.com/newdrugs/fda-approves-filsuvez-birch-triterpenes-topical-gel-epidermolysis-bullosa-6171.html"
  ["blog_url"]=>
  string(114) "https://www.drugs.com/newdrugs/fda-approves-filsuvez-birch-triterpenes-topical-gel-epidermolysis-bullosa-6171.html"
  [15]=>
  string(19) "2023-12-20 04:12:08"
  ["add_date"]=>
  string(19) "2023-12-20 04:12:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

FDA Approves Filsuvez (birch triterpenes) Topical Gel for the Treatment of Epidermolysis B

BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established t

array(40) {
  [0]=>
  string(4) "9116"
  ["article_id"]=>
  string(4) "9116"
  [1]=>
  string(116) "Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes"
  ["article_title"]=>
  string(116) "Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes"
  [2]=>
  string(153) "&#nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage"
  ["short_description"]=>
  string(153) "&#nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage"
  [3]=>
  string(254) "&#nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR low, HER2 low or negative breast cancers&#nlTROPION-Breast05 is evaluating..."
  ["description"]=>
  string(254) "&#nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR low, HER2 low or negative breast cancers&#nlTROPION-Breast05 is evaluating..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(143) "https://www.drugs.com/clinical_trials/two-phase-3-trials-datopotamab-deruxtecan-plus-durvalumab-initiated-patients-across-two-breast-21227.html"
  ["blog_url"]=>
  string(143) "https://www.drugs.com/clinical_trials/two-phase-3-trials-datopotamab-deruxtecan-plus-durvalumab-initiated-patients-across-two-breast-21227.html"
  [15]=>
  string(19) "2023-12-19 07:12:14"
  ["add_date"]=>
  string(19) "2023-12-19 07:12:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across

&#nlTROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoa

array(40) {
  [0]=>
  string(4) "9064"
  ["article_id"]=>
  string(4) "9064"
  [1]=>
  string(126) "FDA Approves Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)"
  ["article_title"]=>
  string(126) "FDA Approves Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)"
  [2]=>
  string(150) "YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FD"
  ["short_description"]=>
  string(150) "YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FD"
  [3]=>
  string(250) "YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved Alyglo (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to..."
  ["description"]=>
  string(250) "YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved Alyglo (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(132) "https://www.drugs.com/newdrugs/fda-approves-alyglo-immune-globulin-intravenous-human-stwk-10-liquid-adults-primary-humoral-6168.html"
  ["blog_url"]=>
  string(132) "https://www.drugs.com/newdrugs/fda-approves-alyglo-immune-globulin-intravenous-human-stwk-10-liquid-adults-primary-humoral-6168.html"
  [15]=>
  string(19) "2023-12-17 12:12:18"
  ["add_date"]=>
  string(19) "2023-12-17 12:12:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

FDA Approves Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with P

YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Fo